Back to top

Image: Bigstock

TG Therapeutics (TGTX) Stock Moves -0.6%: What You Should Know

Read MoreHide Full Article

TG Therapeutics (TGTX - Free Report) closed at $14.79 in the latest trading session, marking a -0.6% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.87%, and the Nasdaq, a tech-heavy index, added 2.77%.

Coming into today, shares of the biopharmaceutical company had lost 21.68% in the past month. In that same time, the Medical sector lost 4.27%, while the S&P 500 lost 5.06%.

TG Therapeutics will be looking to display strength as it nears its next earnings release. In that report, analysts expect TG Therapeutics to post earnings of -$0.36 per share. This would mark year-over-year growth of 29.41%. Meanwhile, our latest consensus estimate is calling for revenue of $4.36 million, up 115.84% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.22 per share and revenue of $82.22 million, which would represent changes of +16.44% and +2853.39%, respectively, from the prior year.

Any recent changes to analyst estimates for TG Therapeutics should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 15.81% lower. TG Therapeutics currently has a Zacks Rank of #3 (Hold).

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 149, putting it in the bottom 41% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions.

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

TG Therapeutics, Inc. (TGTX) - free report >>

Published in